Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. (CHRS) on June 5, 2024, covering events occurring on May 31, 2024. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and related compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased the authorized number of directors from 10 to 11.
- New Appointment: Rita A. Karachun was appointed as a Class II director, effective May 31, 2024. Her term expires at the 2025 annual meeting of stockholders.
- Committee Assignment: Ms. Karachun was appointed to serve on the Audit Committee.
Guidance, Outlook, and Compensation Details
The filing outlines the compensatory arrangements for the new director:
- Cash Retainer: Ms. Karachun is eligible for an annual cash retainer of $60,000 for service on the Board and the Audit Committee.
- Equity Grant: On June 4, 2024, she received an option to purchase 168,000 shares of common stock. The exercise price equals the closing price on June 4, 2024.
- Vesting Schedule: The option vests 1/3 after one year, with the remainder vesting monthly (1/36th per month) over the subsequent two years, fully vesting on the third anniversary.
- Indemnification: The Company expects to enter into a standard director indemnification agreement with Ms. Karachun.
No forward-looking guidance, risk factors, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the closing stock price on June 4, 2024, to determine the exercise price of the 168,000 share option granted to Ms. Karachun.
- Review the Company's non-employee director compensation policy to confirm the $60,000 annual retainer structure.
- Confirm Ms. Karachun's background and potential conflicts of interest, noting her previous role as SVP and Global Controller at Merck & Co., Inc.
- Check subsequent filings for the formal execution of the indemnification agreement referenced in the report.